Interferons, serotonin and neurotoxicity

被引:51
作者
Menkes, DB
MacDonald, JA
机构
[1] Dunedin Publ Hosp, Dunedin, New Zealand
[2] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand
关键词
D O I
10.1017/S0033291799001774
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background. Interferons are a class of cytokines profoundly affecting immune function. Several interferons are now synthesized and used clinically, notably for viral diseases and cancer. In addition to their desired immune effects, interferons cause a number of toxicities, including prominent effects on the nervous system. Methods. This literature review focused on the incidence of depression associated with interferon treatment. Possible neurochemical mechanisms and remedial strategies were also considered. Results. Interferon treatment, particularly with the alpha subtype, is unquestionably linked with depression, but the strength of association is uncertain because of erratic ascertainment and pretreatment co-morbidity. A likely pathogenic mechanism has been described, involving interferon suppression of serotonin synthesis. Controlled treatment trials of interferon-induced depression are not yet available. Conclusions. Neurotoxicity substantially limits the use of interferons. At least some of the risk of depression appears to derive from their anti-serotonergic effects, consistent with the large body of evidence pointing to a general link between serotonin and affective illness. Vigilant detection and aggressive treatment of depression is necessary to optimize interferon treatment of many patients.
引用
收藏
页码:259 / 268
页数:10
相关论文
共 111 条
[31]   Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification [J].
Goldstein, D ;
Hertzog, P ;
Tomkinson, E ;
Couldwell, D ;
McCarville, S ;
Parrish, S ;
Cunningham, P ;
Newell, M ;
Owens, M ;
Cooper, DA .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :858-861
[32]   Human microglia convert L-tryptophan into the neurotoxin quinolinic acid [J].
Heyes, MP ;
Achim, CL ;
Wiley, CA ;
Major, EO ;
Saito, K ;
Markey, SP .
BIOCHEMICAL JOURNAL, 1996, 320 :595-597
[33]   ROYAL-MARSDEN PHASE-III TRIAL OF FLUOROURACIL WITH OR WITHOUT INTERFERON ALFA-2B IN ADVANCED COLORECTAL-CANCER [J].
HILL, M ;
NORMAN, A ;
CUNNINGHAM, D ;
FINDLAY, M ;
NICOLSON, V ;
HILL, A ;
IVESON, A ;
EVANS, C ;
JOFFE, J ;
NICOLSON, M ;
HICKISH, T .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1297-1302
[34]  
Iwagaki H, 1997, ACTA MED OKAYAMA, V51, P233
[35]   COMBINED ALPHA-INTERFERON AND GAMMA-INTERFERON THERAPY FOR MALIGNANT MIDGUT CARCINOID-TUMORS - A PHASE-I-II TRIAL [J].
JANSON, ET ;
KAUPPINEN, HL ;
OBERG, K .
ACTA ONCOLOGICA, 1993, 32 (02) :231-233
[36]   SUICIDE ASSOCIATED WITH ALFA-INTERFERON THERAPY FOR CHRONIC VIRAL-HEPATITIS [J].
JANSSEN, HLA ;
BROUWER, JT ;
VANDERMAST, RC ;
SCHALM, SW .
JOURNAL OF HEPATOLOGY, 1994, 21 (02) :241-243
[37]  
JESSELL TM, 1982, LANCET, V2, P1084
[38]  
Johnson ME, 1998, AM J GASTROENTEROL, V93, P785
[39]   Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy - A prospective study in Japan [J].
Kagaya, A ;
Uchitomi, Y ;
Takezaki, E ;
Fukue, M ;
Tsukano, K ;
Kugaya, A ;
Minagawa, H ;
Takebayashi, M ;
Zensho, H ;
Oyamada, T ;
Yamawaki, S .
NEUROPSYCHOBIOLOGY, 1997, 35 (03) :128-131
[40]   Depression in hospitalized older patients with congestive heart failure [J].
Koenig, HG .
GENERAL HOSPITAL PSYCHIATRY, 1998, 20 (01) :29-43